Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [913]

Influence of cachexia on chemotherapy toxicity

Dr Michael Sawyer – University of Alberta, Canada

Influence of cachexia on chemotherapy toxicity ( Dr Michael Sawyer – University of Alberta, Canada )

Patient involvement in improvements in standard of care

Tom Haswell - VNCRI and NCRN Consumer Liaison Groups

Patient involvement in improvements in standard of care ( Tom Haswell - VNCRI and NCRN Consumer Liaison Groups )

Chemotherapy and radiotherapy in advanced local non-small cell lung cancer

Dr Dirk De Ruysscher – University of Leuven, Netherlands

Chemotherapy and radiotherapy in advanced local non-small cell lung cancer ( Dr Dirk De Ruysscher – University of Leuven, Netherlands )

Analysing the efficacy of treatment through Response Evaluation Criteria in...

Dr Yves Menu – Saint Antoine Hospital, Paris, France

Analysing the efficacy of treatment through Response Evaluation Criteria in Solid Tumors (RECIST) ( Dr Yves Menu – Saint Antoine Hospital, Paris, France )

MET inhibitors for non-small cell lung cancer

Prof Georgio Scagliotti – University of Torino, Italy

MET inhibitors for non-small cell lung cancer ( Prof Georgio Scagliotti – University of Torino, Italy )

Treatment of ALK+ lung cancer with crizotinib, Profile 1007

Dr Alice Shaw – Massachusetts General Hospital, Boston, USA

Phase I study examining PI 3 kinase inhibitor for various tumours

Dr Pamela Munster – University of California, San Francisco, USA

Phase I study examining PI 3 kinase inhibitor for various tumours ( Dr Pamela Munster – University of California, San Francisco, USA )

Phase III trial shows crizotinib superior to single-agent chemotherapy for ALK...

Dr Alice Shaw - Massachusetts General Hospital Cancer Center, Boston, USA

Phase III trial shows crizotinib superior to single-agent chemotherapy for ALK-positive lung cancer ( Dr Alice Shaw - Massachusetts General Hospital Cancer Center, Boston, USA )

Biomarker analysis of MISSION: EGFR lung tumours may benefit from sorafenib

Dr Tony Mok - Chinese University of Hong Kong

Biomarker analysis of MISSION: EGFR lung tumours may benefit from sorafenib ( Dr Tony Mok - Chinese University of Hong Kong )

Sorafenib does not extend overall survival as third or fourth line therapy in...

Dr Luis Paz-Ares - Virgen del Rocio University Hospital in Seville, Spain

Sorafenib does not extend overall survival as third or fourth line therapy in lung cancer – Phase III MISSION trial ( Dr Luis Paz-Ares - Virgen del Rocio University Hospital in Seville, Spain )

Tobacco control and prevention through social media

Joan Bottorff – University of British Columbia, Kelowna, Canada

Tobacco control and prevention through social media ( Joan Bottorff – University of British Columbia, Kelowna, Canada )

Cancer prevention and epidemiology in Russia

Dr David Zardize – Russian National Cancer Research Centre, Moscow, Russia

Cancer prevention and epidemiology in Russia ( Dr David Zardize – Russian National Cancer Research Centre, Moscow, Russia )

More from ecancer